We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of continuous renal replacement therapy (“CRRT”) and other organ support therapies while allowing hospitals the flexibility to meet the requirements of the intensive care unit (ICU).
With the latest launch, Baxter aims to fortify its ground in the global Acute Therapies business.
A Few Words on PrisMax 2
The PrisMax 2 system boasts latest solutions within Baxter’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger, which provides extracorporeal (situated or occurring outside the body) carbon dioxide removal (ECCO2R) therapy to enable acute respiratory dysfunction management.
Further, the PrisMax 2 system provides access to TrueVue digital health solutions to enhance patient care as well as deliver value to hospitals.
The PrisMax 2 and TrueVue will soon be available in the United States and various countries throughout Europe. Further, PrismaLung+ is available in select markets in western Europe, but is not currently cleared or approved for use in the United States.
Significance of the Launch
The PrisMax 2 system uses Baxter’s technology of its market-leading Prismaflex and PrisMax systems, and has been developed on the basis of direct feedback from clinicians and customers worldwide. The system is designed to optimize treatment accuracy, efficacy and system performance.
Apart from offering TrueVue and PrismaLung+, new advancements include updates to the system to offer enhanced visibility of critical information and simplified step-by-step onscreen instructions.
The PrismaLung+ blood-gas exchanger, which can be used on the PrisMax 2 system to deliver ECCO2R therapy, enables treatment of patients who may also require renal replacement therapy or other organ support therapies. This is possible without increasing any complication of delivery, staff training or new capital expenditure requirements.
Per management, the PrisMax 2 system has been developed with the aim of expanding treatment possibilities by making CRRT and other extracorporeal organ support therapies more accessible.
Industry Prospects
Per a report by MarketsAndMarkets, the global CRRT market is projected to reach $1,532.3 million by 2022 from $1,092.5 million in 2017 at a CAGR of 7%. Factors like increasing prevalence of acute renal failure and high prevalence of diabetes are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen Baxter’s global business.
Notable Developments
Of late, Baxter has witnessed a few notable developments across its businesses.
The company, in April, reported solid worldwide sales during first-quarter 2021 with the Acute Therapies segment being the primary driver.
Baxter, in March, received the FDA’s clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine. Notably, the AK 98 machine is designed to be a portable and easy-to-use system for administering hemodialysis treatments.
The same month, the company entered into an agreement with Moderna, Inc. (MRNA - Free Report) with respect to the COVID-19 vaccines. Per the agreement, Baxter BioPharma Solutions would provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of Moderna’s vaccine in 2021.
Price Performance
Shares of the company have lost 9.7% in the past year against the industry’s 14.8% growth and the S&P 500's 38.5% rise.
Illumina’s long-term earnings growth rate is estimated at 7%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies
Baxter International Inc. (BAX - Free Report) recently announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of continuous renal replacement therapy (“CRRT”) and other organ support therapies while allowing hospitals the flexibility to meet the requirements of the intensive care unit (ICU).
With the latest launch, Baxter aims to fortify its ground in the global Acute Therapies business.
A Few Words on PrisMax 2
The PrisMax 2 system boasts latest solutions within Baxter’s TrueVue digital health portfolio, as well as the PrismaLung+ blood-gas exchanger, which provides extracorporeal (situated or occurring outside the body) carbon dioxide removal (ECCO2R) therapy to enable acute respiratory dysfunction management.
Further, the PrisMax 2 system provides access to TrueVue digital health solutions to enhance patient care as well as deliver value to hospitals.
The PrisMax 2 and TrueVue will soon be available in the United States and various countries throughout Europe. Further, PrismaLung+ is available in select markets in western Europe, but is not currently cleared or approved for use in the United States.
Significance of the Launch
The PrisMax 2 system uses Baxter’s technology of its market-leading Prismaflex and PrisMax systems, and has been developed on the basis of direct feedback from clinicians and customers worldwide. The system is designed to optimize treatment accuracy, efficacy and system performance.
Apart from offering TrueVue and PrismaLung+, new advancements include updates to the system to offer enhanced visibility of critical information and simplified step-by-step onscreen instructions.
The PrismaLung+ blood-gas exchanger, which can be used on the PrisMax 2 system to deliver ECCO2R therapy, enables treatment of patients who may also require renal replacement therapy or other organ support therapies. This is possible without increasing any complication of delivery, staff training or new capital expenditure requirements.
Per management, the PrisMax 2 system has been developed with the aim of expanding treatment possibilities by making CRRT and other extracorporeal organ support therapies more accessible.
Industry Prospects
Per a report by MarketsAndMarkets, the global CRRT market is projected to reach $1,532.3 million by 2022 from $1,092.5 million in 2017 at a CAGR of 7%. Factors like increasing prevalence of acute renal failure and high prevalence of diabetes are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen Baxter’s global business.
Notable Developments
Of late, Baxter has witnessed a few notable developments across its businesses.
The company, in April, reported solid worldwide sales during first-quarter 2021 with the Acute Therapies segment being the primary driver.
Baxter, in March, received the FDA’s clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine. Notably, the AK 98 machine is designed to be a portable and easy-to-use system for administering hemodialysis treatments.
The same month, the company entered into an agreement with Moderna, Inc. (MRNA - Free Report) with respect to the COVID-19 vaccines. Per the agreement, Baxter BioPharma Solutions would provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of Moderna’s vaccine in 2021.
Price Performance
Shares of the company have lost 9.7% in the past year against the industry’s 14.8% growth and the S&P 500's 38.5% rise.
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Illumina, Inc. (ILMN - Free Report) and DaVita Inc. (DVA - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Illumina’s long-term earnings growth rate is estimated at 7%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>